Active Biotech AB (publ)

OM:ACTI Stock Report

Market Cap: SEK 314.9m

Active Biotech Past Earnings Performance

Past criteria checks 0/6

Active Biotech's earnings have been declining at an average annual rate of -7.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been declining at an average rate of 69.8% per year.

Key information

-7.7%

Earnings growth rate

7.6%

EPS growth rate

Biotechs Industry Growth0.7%
Revenue growth rate-69.8%
Return on equity-2,971.4%
Net Marginn/a
Next Earnings Update13 Feb 2025

Recent past performance updates

Recent updates

Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Jun 05
Here's Why We're A Bit Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Feb 19
Is Active Biotech (STO:ACTI) In A Good Position To Invest In Growth?

Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Jul 27
Active Biotech (STO:ACTI) Will Have To Spend Its Cash Wisely

Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

May 07
Here's Why Active Biotech (STO:ACTI) Must Use Its Cash Wisely

Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

Nov 09
Here's Why We're Not Too Worried About Active Biotech's (STO:ACTI) Cash Burn Situation

We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

May 03
We're Hopeful That Active Biotech (STO:ACTI) Will Use Its Cash Wisely

We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Jan 18
We're Keeping An Eye On Active Biotech's (STO:ACTI) Cash Burn Rate

Revenue & Expenses Breakdown

How Active Biotech makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

OM:ACTI Revenue, expenses and earnings (SEK Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 240-421329
30 Jun 240-441331
31 Mar 240-451432
31 Dec 230-461433
30 Sep 230-481633
30 Jun 230-511636
31 Mar 230-541539
31 Dec 220-581543
30 Sep 220-601544
30 Jun 220-571541
31 Mar 220-561640
31 Dec 210-501535
30 Sep 216-381430
30 Jun 216-351328
31 Mar 216-321325
31 Dec 207-321326
30 Sep 201-391327
30 Jun 202-401327
31 Mar 203-361326
31 Dec 198-341228
30 Sep 1912-321129
30 Jun 1916-311133
31 Mar 1921-351038
31 Dec 1820-371139
30 Sep 1821-881140
30 Jun 1821-881140
31 Mar 1820-1031945
31 Dec 1720-1092049
30 Sep 1722-632156
30 Jun 1721-672258
31 Mar 1720-591658
31 Dec 1619-601658
30 Sep 1617-861671
30 Jun 1618-971782
31 Mar 1617-15217128
31 Dec 1516-19418176
30 Sep 1514-21017202
30 Jun 1512-24317233
31 Mar 1511-22918220
31 Dec 1410-23217222
30 Sep 1412-25718247
30 Jun 14116-17118268
31 Mar 14116-19417290
31 Dec 13116-21217308

Quality Earnings: ACTI is currently unprofitable.

Growing Profit Margin: ACTI is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ACTI is unprofitable, and losses have increased over the past 5 years at a rate of 7.7% per year.

Accelerating Growth: Unable to compare ACTI's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ACTI is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-20.8%).


Return on Equity

High ROE: ACTI has a negative Return on Equity (-2971.43%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies